Is Vismodegib a targeted drug?

Vismodegib (Vismodegib) is the first Hedgehog signaling pathway-targeted inhibitor approved by the U.S. Food and Drug Administration (FDA) . It is also the first drug approved for the treatment of metastatic or locally advanced unresectable basal cell carcinoma (BCC) . Its rapid launch was largely based on the strength of a non-randomized 104-patient study whose primary endpoint was response rate.

This approval comes almost 5 years after Vimodegib was first used in humans In this study, the response rates in the metastatic and locally advanced cohorts were 30.3% and 42.9%, respectively, and the median progression-free survival in both cohorts was 9.5 months. The bioavailability of Vimodegib is approximately 32%, and the peak time is approximately 2.4 days. More than 98% of drugs circulate as the original compound. Once absorbed, its distribution volume (Vd) is between 16-26.6L and is highly protein-bound (greater than 99%) to serum albumin and α-acid glycoprotein (AAG). Vimodegib is metabolized by oxidation, glucuronidation, and ring cleavage. It is a minor substrate of CYP2C9 and CYP3A4. The elimination half-life after a single dose is approximately 12 days, but after continuous daily dosing, the half-life becomes 4 days before being eliminated primarily in feces (82%) and urine (4%).

The original drug of Vimodegib is not currently on the market in the country, so it cannot be included in medical insurance. Overseas, Vimodegiboriginal drug has Turkish version and European version, specificationsThe price of 150mg*28 capsules per box may be around RMB 10,000-30,000 (the price may fluctuate due to the exchange rate). The price is very expensive, and there are currently no generic versions of Vimodegib. For more drug information and specific prices, please consult Yaodei Medical Consultants.